Hormone replacement therapy and breast cancer

Smellie, W. J. B.; Thomas, J. M.

doi:10.1111/j.1471-0528.1993.tb15261.x

BJOG

1993

DOI: 10.1111/j.1471-0528.1993.tb15261.x

|View full text |Cite

Hormone replacement therapy and breast cancer

W. J. B. Smellie

J. M. Thomas

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1993

2002

Publication Types

Select...

Article5

Relationship

Self Cite1

Independent4

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We accept, and state in our text Smellie & Thomas (1993), that it is not possible to be confident about the long term safety of hormone replacement therapy (HRT) in the same way as it is in the short term therapy group of patients treated for less than ten years. Grady and Ernster (1991) amalgamated the findings of all the recent analyses and suggest that a large trial, producing results that differ markedly from those found in previous trials, would be required to alter the conclusion that short term use of HRT causes few, if any, extra cases of breast cancer.…”

mentioning

confidence: 96%

Authors’ reply

Smellie

Thomas

1994

BJOG

Self Cite

View full text Add to dashboard Cite

A metaanalysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265, [1985][1986][1987][1988][1989][1990]. Authors' replySir, We accept, and state in our text Smellie & Thomas (1993), that it is not possible to be confident about the long term safety of hormone replacement therapy (HRT) in the same way as it is in the short term therapy group of patients treated for less than ten years. Grady and Ernster (1991) amalgamated the findings of all the recent analyses and suggest that a large trial, producing results that differ markedly from those found in previous trials, would be required to alter the conclusion that short term use of HRT causes few, if any, extra cases of breast cancer. Although unaware of the planned trials into the safety of HRT referred to, we still doubt the ability of such trials to be double-blind because of the obvious manifestations of HRT. We shall welcome their results in 15 years, and in the meantime have to accept the limitations of observational trials. A randomised trial of 45 minute and 15 minute incremental oxytocin infusion regimes for the induction of labour in women of high paritySir, We read with interest the paper by Orhue (February 1993) which is also relevant to obstetricians in developed countries. The paper demonstrates the risks of 15 minute compared with 45 minute oxytocin infusion increments for women of high parity. These risks outweigh the slight delay in induction-delivery interval. We believe the conclusions can be extended. It has been demonstrated that in primiparous and multiparous women, regimens involving dose increment intervals less than 30 minutes have no effect on the induction-delivery interval and are associated with an increased incidence of hyperstimulation and more frequent caesarean section due to fetal heart rate abnormalities ( (1992) is welcome in that it helps to shift the focus of attention away from single assessment of fetal size to dynamic assessment of size when growth is to be assessed. I find the comments of Gardosi (1993) rather unhelpful as he seems to have missed the whole point of this wellconducted study. In being fixated with the use of "appropriately derived" birthweight charts, he has overconcentrated his criticisms on the choice of birthweight charts. Furthermore, his criticism that there were only 10 small for gestational age (SGA) babies in the study suggests that he equates SGA with IUGR, the very point that this study was trying to get away from. The demonstration that a falloff in growth amongst appropriate for gestational age babies is associated with significant perinatal morbidity suggests that obstetric practice should take into consideration this group of babies. Perhaps one way in which Danielian and co-workers can overcome the criticisms of Gardosi (1993) would be to evaluate perinatal morbidity in fetuses who have been assessed by serial ultrasound scans, thereby obviating the use of birthweight and birthweight charts altogether? T. C. Chang

show abstract

mentioning

confidence: 96%

Authors’ reply

Smellie

Thomas

1994

BJOG

Self Cite

View full text Add to dashboard Cite

show abstract

Estrogen replacement therapy in women at increased risk for breast cancer

Vassilopoulou‐Sellin

1993

Breast Cancer Res Tr

View full text Add to dashboard Cite

The topic of estrogen replacement (ERT) after the onset of menopause remains controversial and charged with considerable emotion within both the medical community and the lay public. This is especially true for women at increased risk for breast cancer as well as those who reach menopause after the diagnosis of this disease. ERT clearly protects postmenopausal women from the morbidity and mortality of cardiovascular disease and osteoporosis, and it alleviates vasomotor and genitourinary symptoms. However, there remains uncertainty whether and for which subgroups of women these benefits may be offset by a potential increased risk for breast cancer. With screening programs, breast cancer is being diagnosed at an earlier stage: with improved therapy, survival rates are improving. Adjuvant chemotherapy is increasingly incorporated in the treatment program of localized disease and accelerates the arrival of menopause. Thus, more and younger women with excellent survival prognosis will develop early menopause after treatment for early breast cancer. For these women, the decision regarding ERT is likely to affect the quality and quantity of their life for several decades. It is important to weigh the relative risks and benefits of ERT for each individual woman in order to develop a meaningful health maintenance plan.

show abstract

Hormonal Manipulations and Breast Cancer

Benshushan¹,

Brzezinski²

2002

Obstetrical and Gynecological Survey

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Hormone replacement therapy and breast cancer

Cited by 5 publications

References 56 publications

Authors’ reply

Authors’ reply

Estrogen replacement therapy in women at increased risk for breast cancer

Hormonal Manipulations and Breast Cancer

Contact Info

Product

Resources

About